{"id":725057,"date":"2023-01-23T13:28:18","date_gmt":"2023-01-23T18:28:18","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/catalyst-pharmaceuticals-comments-on-fdas-announcement-of-its-position-on-orphan-drug-exclusivity-in-light-of-the-11th-circuit-decision-in-catalyst-pharmaceuticals-inc-v-becerra\/"},"modified":"2023-01-23T13:28:18","modified_gmt":"2023-01-23T18:28:18","slug":"catalyst-pharmaceuticals-comments-on-fdas-announcement-of-its-position-on-orphan-drug-exclusivity-in-light-of-the-11th-circuit-decision-in-catalyst-pharmaceuticals-inc-v-becerra","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/catalyst-pharmaceuticals-comments-on-fdas-announcement-of-its-position-on-orphan-drug-exclusivity-in-light-of-the-11th-circuit-decision-in-catalyst-pharmaceuticals-inc-v-becerra\/","title":{"rendered":"Catalyst Pharmaceuticals Comments on FDA’s Announcement of its Position on Orphan Drug Exclusivity In Light of the 11th Circuit Decision in Catalyst Pharmaceuticals, Inc. v. Becerra"},"content":{"rendered":"
\n

\n Announced Earlier Today<\/em>-Notice Received from ANDA Filer for FIRDAPSE\u00ae<\/p>\n

CORAL GABLES, Fla., Jan. 23, 2023 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc.<\/strong>\u00a0(“Catalyst”) (NASDAQ: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today commented on the FDA’s notice setting forth its position on Orphan Drug Exclusivity in light of the 11th<\/sup> Circuit’s decision in Catalyst Pharmaceuticals, Inc. v. Becerra<\/u>. The FDA announcement states that while the FDA is complying with the 11th<\/sup> Circuit decision in Catalyst’s favor with respect to FIRDAPSE\u00ae, the FDA intends to continue to apply its regulations tying the scope of orphan drug exclusivity to the uses or indications for which a drug is approved with respect to other orphan drugs. Catalyst reports that it is not affected by the FDA’s newly announced position and that the FDA’s announcement confirms the FDA’s previous decision to set aside the approval of RUZURGI\u00ae as a result of the 11th<\/sup> Circuit’s decision. Further, Catalyst acquired the United States rights to RUZURGI\u00ae, including all intellectual property relating thereto, in July 2022. Finally, Catalyst’s supplemental New Drug Application expanding its label for FIRDAPSE\u00ae to children ages 6-17 was approved by the FDA in September 2022.<\/p>\n

Separately, Catalyst announced this morning that an abbreviated new drug application has been filed by Teva Pharmaceuticals, Inc., seeking authorization from the FDA to manufacture, use, or sell a generic version of FIRDAPSE\u00ae in the United States. As Catalyst has previously reported, the filing of a Paragraph IV challenge to FIRDAPSE\u00ae was not unexpected, and Catalyst intends to vigorously enforce its intellectual property rights relating to FIRDAPSE\u00ae.<\/p>\n

\n About\u00a0Catalyst Pharmaceuticals<\/strong>
\n
Catalyst Pharmaceuticals\u00a0is a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases. With exceptional patient focus, Catalyst is committed to developing a robust pipeline of cutting-edge, best-in-class medicines for rare diseases. Catalyst’s New Drug Application for FIRDAPSE\u00a0(amifampridine) Tablets 10 mg for the treatment of adults with Lambert-Eaton myasthenic syndrome (“LEMS”) was approved in 2018 by the\u00a0U.S. Food & Drug Administration\u00a0and FIRDAPSE\u00a0is commercially available in\u00a0the United States\u00a0as a treatment for adults and children ages six to seventeen with LEMS. Further,\u00a0Canada’s\u00a0national healthcare regulatory agency,\u00a0Health Canada, has approved the use of FIRDAPSE\u00a0for the treatment of adult patients in\u00a0Canada\u00a0with LEMS.<\/p>\n

For more information, visit Catalyst’s website at\u00a0www.catalystpharma.com<\/u><\/strong><\/a>.<\/p>\n

\n Forward-Looking Statements<\/strong>\n <\/p>\n

This press release contains forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties, which may cause Catalyst’s actual results in future periods to differ materially from forecasted results. A number of factors, including those set forth in Catalyst’s Annual Report on Form 10-K for the fiscal year 2021, its Quarterly Report on Form 10-Q, and its other filings with the\u00a0U.S. Securities and Exchange Commission\u00a0(“SEC”), could adversely affect Catalyst. Copies of Catalyst’s filings with the\u00a0SEC\u00a0are available from the\u00a0SEC, may be found on Catalyst’s website, or may be obtained upon request from Catalyst. Catalyst does not undertake any obligation to update the information contained herein, which speaks only as of this date.<\/p>\n


\n
\n \n <\/div>\n

\n
Contact information:\r\n\r\nMedia Contact\r\nDavid Schull, Russo Partners\r\n(858) 717-2310\r\ndavid.schull@russopartnersllc.com\r\n\r\nInvestor Contact\r\nMary Coleman, Catalyst Pharmaceuticals, Inc.\r\n(305) 420-3200\r\nmcoleman@catalystpharma.com<\/pre>\n<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"
Announced Earlier Today-Notice Received from ANDA Filer for FIRDAPSE\u00ae CORAL GABLES, Fla., Jan. 23, 2023 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc.\u00a0(“Catalyst”) (NASDAQ: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today commented on the FDA’s notice setting forth its position on Orphan Drug Exclusivity in light of the 11th Circuit’s decision in Catalyst Pharmaceuticals, Inc. v. Becerra. The FDA announcement states that while the FDA is complying with the 11th Circuit decision in Catalyst’s favor with respect to FIRDAPSE\u00ae, the FDA intends to continue to apply its regulations tying the scope of orphan drug exclusivity to the uses or indications for which a drug is approved with respect to … <\/p>\n
Continue reading “Catalyst Pharmaceuticals Comments on FDA’s Announcement of its Position on Orphan Drug Exclusivity In Light of the 11th Circuit Decision in Catalyst Pharmaceuticals, Inc. v. Becerra”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-725057","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nCatalyst Pharmaceuticals Comments on FDA's Announcement of its Position on Orphan Drug Exclusivity In Light of the 11th Circuit Decision in Catalyst Pharmaceuticals, Inc. v. Becerra - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/catalyst-pharmaceuticals-comments-on-fdas-announcement-of-its-position-on-orphan-drug-exclusivity-in-light-of-the-11th-circuit-decision-in-catalyst-pharmaceuticals-inc-v-becerra\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Catalyst Pharmaceuticals Comments on FDA's Announcement of its Position on Orphan Drug Exclusivity In Light of the 11th Circuit Decision in Catalyst Pharmaceuticals, Inc. v. Becerra - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Announced Earlier Today-Notice Received from ANDA Filer for FIRDAPSE\u00ae CORAL GABLES, Fla., Jan. 23, 2023 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc.\u00a0(“Catalyst”) (NASDAQ: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today commented on the FDA’s notice setting forth its position on Orphan Drug Exclusivity in light of the 11th Circuit’s decision in Catalyst Pharmaceuticals, Inc. v. Becerra. The FDA announcement states that while the FDA is complying with the 11th Circuit decision in Catalyst’s favor with respect to FIRDAPSE\u00ae, the FDA intends to continue to apply its regulations tying the scope of orphan drug exclusivity to the uses or indications for which a drug is approved with respect to … Continue reading "Catalyst Pharmaceuticals Comments on FDA’s Announcement of its Position on Orphan Drug Exclusivity In Light of the 11th Circuit Decision in Catalyst Pharmaceuticals, Inc. v. Becerra"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/catalyst-pharmaceuticals-comments-on-fdas-announcement-of-its-position-on-orphan-drug-exclusivity-in-light-of-the-11th-circuit-decision-in-catalyst-pharmaceuticals-inc-v-becerra\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-01-23T18:28:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODczNDgxOCM1MzY5NjYwIzIwMTk0OTE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/catalyst-pharmaceuticals-comments-on-fdas-announcement-of-its-position-on-orphan-drug-exclusivity-in-light-of-the-11th-circuit-decision-in-catalyst-pharmaceuticals-inc-v-becerra\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/catalyst-pharmaceuticals-comments-on-fdas-announcement-of-its-position-on-orphan-drug-exclusivity-in-light-of-the-11th-circuit-decision-in-catalyst-pharmaceuticals-inc-v-becerra\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Catalyst Pharmaceuticals Comments on FDA’s Announcement of its Position on Orphan Drug Exclusivity In Light of the 11th Circuit Decision in Catalyst Pharmaceuticals, Inc. v. Becerra\",\"datePublished\":\"2023-01-23T18:28:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/catalyst-pharmaceuticals-comments-on-fdas-announcement-of-its-position-on-orphan-drug-exclusivity-in-light-of-the-11th-circuit-decision-in-catalyst-pharmaceuticals-inc-v-becerra\\\/\"},\"wordCount\":540,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/catalyst-pharmaceuticals-comments-on-fdas-announcement-of-its-position-on-orphan-drug-exclusivity-in-light-of-the-11th-circuit-decision-in-catalyst-pharmaceuticals-inc-v-becerra\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODczNDgxOCM1MzY5NjYwIzIwMTk0OTE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/catalyst-pharmaceuticals-comments-on-fdas-announcement-of-its-position-on-orphan-drug-exclusivity-in-light-of-the-11th-circuit-decision-in-catalyst-pharmaceuticals-inc-v-becerra\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/catalyst-pharmaceuticals-comments-on-fdas-announcement-of-its-position-on-orphan-drug-exclusivity-in-light-of-the-11th-circuit-decision-in-catalyst-pharmaceuticals-inc-v-becerra\\\/\",\"name\":\"Catalyst Pharmaceuticals Comments on FDA's Announcement of its Position on Orphan Drug Exclusivity In Light of the 11th Circuit Decision in Catalyst Pharmaceuticals, Inc. v. Becerra - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/catalyst-pharmaceuticals-comments-on-fdas-announcement-of-its-position-on-orphan-drug-exclusivity-in-light-of-the-11th-circuit-decision-in-catalyst-pharmaceuticals-inc-v-becerra\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/catalyst-pharmaceuticals-comments-on-fdas-announcement-of-its-position-on-orphan-drug-exclusivity-in-light-of-the-11th-circuit-decision-in-catalyst-pharmaceuticals-inc-v-becerra\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODczNDgxOCM1MzY5NjYwIzIwMTk0OTE=\",\"datePublished\":\"2023-01-23T18:28:18+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/catalyst-pharmaceuticals-comments-on-fdas-announcement-of-its-position-on-orphan-drug-exclusivity-in-light-of-the-11th-circuit-decision-in-catalyst-pharmaceuticals-inc-v-becerra\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/catalyst-pharmaceuticals-comments-on-fdas-announcement-of-its-position-on-orphan-drug-exclusivity-in-light-of-the-11th-circuit-decision-in-catalyst-pharmaceuticals-inc-v-becerra\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/catalyst-pharmaceuticals-comments-on-fdas-announcement-of-its-position-on-orphan-drug-exclusivity-in-light-of-the-11th-circuit-decision-in-catalyst-pharmaceuticals-inc-v-becerra\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODczNDgxOCM1MzY5NjYwIzIwMTk0OTE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODczNDgxOCM1MzY5NjYwIzIwMTk0OTE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/catalyst-pharmaceuticals-comments-on-fdas-announcement-of-its-position-on-orphan-drug-exclusivity-in-light-of-the-11th-circuit-decision-in-catalyst-pharmaceuticals-inc-v-becerra\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Catalyst Pharmaceuticals Comments on FDA’s Announcement of its Position on Orphan Drug Exclusivity In Light of the 11th Circuit Decision in Catalyst Pharmaceuticals, Inc. v. Becerra\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Catalyst Pharmaceuticals Comments on FDA's Announcement of its Position on Orphan Drug Exclusivity In Light of the 11th Circuit Decision in Catalyst Pharmaceuticals, Inc. v. Becerra - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/catalyst-pharmaceuticals-comments-on-fdas-announcement-of-its-position-on-orphan-drug-exclusivity-in-light-of-the-11th-circuit-decision-in-catalyst-pharmaceuticals-inc-v-becerra\/","og_locale":"en_US","og_type":"article","og_title":"Catalyst Pharmaceuticals Comments on FDA's Announcement of its Position on Orphan Drug Exclusivity In Light of the 11th Circuit Decision in Catalyst Pharmaceuticals, Inc. v. Becerra - Market Newsdesk","og_description":"Announced Earlier Today-Notice Received from ANDA Filer for FIRDAPSE\u00ae CORAL GABLES, Fla., Jan. 23, 2023 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc.\u00a0(“Catalyst”) (NASDAQ: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today commented on the FDA’s notice setting forth its position on Orphan Drug Exclusivity in light of the 11th Circuit’s decision in Catalyst Pharmaceuticals, Inc. v. Becerra. The FDA announcement states that while the FDA is complying with the 11th Circuit decision in Catalyst’s favor with respect to FIRDAPSE\u00ae, the FDA intends to continue to apply its regulations tying the scope of orphan drug exclusivity to the uses or indications for which a drug is approved with respect to … Continue reading \"Catalyst Pharmaceuticals Comments on FDA’s Announcement of its Position on Orphan Drug Exclusivity In Light of the 11th Circuit Decision in Catalyst Pharmaceuticals, Inc. v. Becerra\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/catalyst-pharmaceuticals-comments-on-fdas-announcement-of-its-position-on-orphan-drug-exclusivity-in-light-of-the-11th-circuit-decision-in-catalyst-pharmaceuticals-inc-v-becerra\/","og_site_name":"Market Newsdesk","article_published_time":"2023-01-23T18:28:18+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODczNDgxOCM1MzY5NjYwIzIwMTk0OTE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/catalyst-pharmaceuticals-comments-on-fdas-announcement-of-its-position-on-orphan-drug-exclusivity-in-light-of-the-11th-circuit-decision-in-catalyst-pharmaceuticals-inc-v-becerra\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/catalyst-pharmaceuticals-comments-on-fdas-announcement-of-its-position-on-orphan-drug-exclusivity-in-light-of-the-11th-circuit-decision-in-catalyst-pharmaceuticals-inc-v-becerra\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Catalyst Pharmaceuticals Comments on FDA’s Announcement of its Position on Orphan Drug Exclusivity In Light of the 11th Circuit Decision in Catalyst Pharmaceuticals, Inc. v. Becerra","datePublished":"2023-01-23T18:28:18+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/catalyst-pharmaceuticals-comments-on-fdas-announcement-of-its-position-on-orphan-drug-exclusivity-in-light-of-the-11th-circuit-decision-in-catalyst-pharmaceuticals-inc-v-becerra\/"},"wordCount":540,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/catalyst-pharmaceuticals-comments-on-fdas-announcement-of-its-position-on-orphan-drug-exclusivity-in-light-of-the-11th-circuit-decision-in-catalyst-pharmaceuticals-inc-v-becerra\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODczNDgxOCM1MzY5NjYwIzIwMTk0OTE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/catalyst-pharmaceuticals-comments-on-fdas-announcement-of-its-position-on-orphan-drug-exclusivity-in-light-of-the-11th-circuit-decision-in-catalyst-pharmaceuticals-inc-v-becerra\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/catalyst-pharmaceuticals-comments-on-fdas-announcement-of-its-position-on-orphan-drug-exclusivity-in-light-of-the-11th-circuit-decision-in-catalyst-pharmaceuticals-inc-v-becerra\/","name":"Catalyst Pharmaceuticals Comments on FDA's Announcement of its Position on Orphan Drug Exclusivity In Light of the 11th Circuit Decision in Catalyst Pharmaceuticals, Inc. v. Becerra - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/catalyst-pharmaceuticals-comments-on-fdas-announcement-of-its-position-on-orphan-drug-exclusivity-in-light-of-the-11th-circuit-decision-in-catalyst-pharmaceuticals-inc-v-becerra\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/catalyst-pharmaceuticals-comments-on-fdas-announcement-of-its-position-on-orphan-drug-exclusivity-in-light-of-the-11th-circuit-decision-in-catalyst-pharmaceuticals-inc-v-becerra\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODczNDgxOCM1MzY5NjYwIzIwMTk0OTE=","datePublished":"2023-01-23T18:28:18+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/catalyst-pharmaceuticals-comments-on-fdas-announcement-of-its-position-on-orphan-drug-exclusivity-in-light-of-the-11th-circuit-decision-in-catalyst-pharmaceuticals-inc-v-becerra\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/catalyst-pharmaceuticals-comments-on-fdas-announcement-of-its-position-on-orphan-drug-exclusivity-in-light-of-the-11th-circuit-decision-in-catalyst-pharmaceuticals-inc-v-becerra\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/catalyst-pharmaceuticals-comments-on-fdas-announcement-of-its-position-on-orphan-drug-exclusivity-in-light-of-the-11th-circuit-decision-in-catalyst-pharmaceuticals-inc-v-becerra\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODczNDgxOCM1MzY5NjYwIzIwMTk0OTE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODczNDgxOCM1MzY5NjYwIzIwMTk0OTE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/catalyst-pharmaceuticals-comments-on-fdas-announcement-of-its-position-on-orphan-drug-exclusivity-in-light-of-the-11th-circuit-decision-in-catalyst-pharmaceuticals-inc-v-becerra\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Catalyst Pharmaceuticals Comments on FDA’s Announcement of its Position on Orphan Drug Exclusivity In Light of the 11th Circuit Decision in Catalyst Pharmaceuticals, Inc. v. Becerra"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/725057","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=725057"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/725057\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=725057"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=725057"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=725057"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}